Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04681417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Study acronym: RETINO 2018
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jan 10, 2024, no change to tracked fieldsv7-v8
  2. Site contacts updated at 2 of 28 sitesv6
  3. Site contacts updated at 1 of 28 sitesv5
  4. Interventions: Carboplatin administered on Day 1 (Drug), Cryotherapy (local treatment) (Device), Intravitreal Melphalan chemotherapy injections (local… to Carboplatin administered on Day 1 (Drug), Cryotherapy (local treatment) (Device), Intravitreal Melphalan chemotherapy injections (local…
    • Study description expanded, about 7 words
    v4
  5. Start date: Feb 11, 2021 to Mar 25, 2021
    • Site details revised at 22 of 28 sites
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 20, 2021 to Feb 11, 2021
    • Site details revised at 28 of 28 sites
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients: * Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments. * Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.
Trial Details
NCT Number NCT04681417
Lead Sponsor Institut Curie
Collaborators: Fondation Rothschild Paris
Conditions
(from sponsor)		 Retinoblastoma
Related terms Retinoblastoma
Enrollment 225 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov